Lennox-Gastaut syndrome therapeutics currently exhibits a proliferating pipeline with eight active therapeutic candidates in different stages of development.
According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; has lesser risk of systemic infections; and is inexpensive in nature. Administration of therapeutics for LGS through oral route have shown promising results in the clinical studies. Also, maximum number of drugs in the pipeline are targeting GABA receptors and stimulating its mechanism of action.
Download sample copy of this report at: https://www.pharmaproff.com/request-sample/1214
It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of LGS therapeutics. These technologies play an important role in the drug development thereby helping the companies to develop more specific and effective targeted therapies. For instance, the focus of Aquestive Therapeutics Inc’s PharmFilm drug delivery technology platform and Supernus Pharmaceuticals Inc.’s Microtrol technology is to ensure faster onset of action, improved tolerability, lower dose exposures with equivalent efficacy, consistent, accurate dosing, ease of use, and improved adherence to medication over time.
Some of the key players involved in the development of LGS therapeutics in the late and mid stages of development include Zogenix Inc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, and Marinus Pharmaceuticals Inc.
This post was originally published on Financial Sector